Bruce C Carleton

Nov 18, 2024 | nature.com | Jeanette Cooper |Christine Fahim |Bruce C Carleton

AbstractPharmacogenetic (PGx) testing can enhance drug safety, improve efficacy, and reduce the risk of toxicity. However, the implementation of PGx testing in Canadian pediatric oncology centers has been limited. To address this gap, the aim of this study was to assess the barriers and facilitators to implementing PGx testing for three oncology drugs in eight Canadian pediatric oncology centers and identify strategies that could be used to support PGx testing implementation.

Nov 4, 2024 | nature.com | Kheireddin Mufti |Catrina M. Loucks |Shahrad R. Rassekh |Bruce C Carleton

AbstractVincristine-induced peripheral neuropathy is a common and highly debilitating toxicity from vincristine treatment that affects quality of life and often requires dose reduction, potentially affecting survival. Although previous studies demonstrated genetic factors are associated with vincristine neuropathy risk, the clinical relevance of most identified variants is limited by small sample sizes and unclear clinical phenotypes.

May 19, 2023 | onlinelibrary.wiley.com | Daniel B. Horton |Bruce C Carleton |Pharmaceutical Outcomes Programme |Madlen Gazarian

ORIGINAL ARTICLE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/pds.5640.